The Vanguard Group, Inc. has recently announced that it has increased stake in Perspective Therapeutics Inc (AMEX:CATX) by 0.78%. After grabbing 12.74 million shares, the institutional investor is now in possession of 99189.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.54% having worth around $3.25 million. Moreover, Baker Bros. Advisors LP increased its share by 5.32 million to have a control over 7.64 million shares. And Geode Capital Management LLC raised its holdings to 66750.0 shares by acquiring 2.52 million shares or 0.90% of the stake.
Perspective Therapeutics Inc (CATX) concluded trading on 12/28/23 at a closing price of $0.46, with 2.28 million shares of worth about $1.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.48% during that period and on Thursday the price saw a loss of about -4.17%. Currently the company’s common shares owned by public are about 280.57M shares, out of which, 202.38M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the CATX stock and their offered price forecasts bring an average price target of $1.30. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.40 and could fall to a lowest price of $1.20. The stock’s current price level is 64.62% above of average price target set by the analysts, while a rise to estimated low would result in gain of 61.67% for the stock. However, touching the estimated high of $1.40 would mean a gain of 67.14% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 187,500 shares in 2 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Perspective Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 9.67 million shares of worth totaling $2.47 million. The company recently came buying 0.0 shares which brought its stake up to 3.45% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 60727.0 shares, after which its hold over company’s outstanding shares expand to 0.99%, leaving 2.77 million shares with the mutual fund that have a worth of about $0.71 million. Fidelity Extended Market Index Fu, after buying 1.46 million shares, have now control over 0.52% of the stake in the company. It holds 0.0 shares of worth $0.37 million.
Perspective Therapeutics Inc (AMEX: CATX) started trading at $0.50, above $0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 0.4999, or with a loss of -4.17%. Stock saw a price change of 33.04% in past 5 days and over the past one month there was a price change of 79.28%. Year-to-date (YTD), CATX shares are showing a performance of 84.14% which increased to 76.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $0.73 during that period. The average intraday trading volume for Perspective Therapeutics Inc shares is 398.08K. The stock is currently trading 53.88% above its 20-day simple moving average (SMA20), while that difference is up 64.79% for SMA50 and it goes to -1.36% lower than SMA200.
The Vanguard Group, Inc. acquired 12.74 million shares of Perspective Therapeutics Inc having value of about $3.25 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 99189.0 shares in the company valued at close to $45626.94, or have control over 0.78% stake in the company. Perspective Therapeutics Inc (AMEX: CATX) currently have 280.57M outstanding shares and institutions hold larger chunk of about 13.04% of that. Holding of mutual funds in the company is about 5.59% while other institutional holders and individual stake holders have control over 7.46% and 1.97% of the stake respectively.
The stock has a current market capitalization of $127.66M and its 3Y-monthly beta is at 1.69. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 2.55 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CATX, volatility over the week remained 12.85% while standing at 10.47% over the month.
Analysts are in expectations that Perspective Therapeutics Inc (CATX) stock would likely to be making an EPS of -$0.04 in the current quarter, while forecast for next quarter EPS is -$0.03 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.04 which is -$0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.02 in the same quarter a year ago.
Analysts at 2 brokerage firms have issued recommendations for the Perspective Therapeutics Inc (CATX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
